Chewed Versus Swallowed Ticagrelor in P2Y12 Inhibitor-Naive Patients Undergoing Percutaneous Coronary Intervention.

ABSTRACT:

Purpose

Dual antiplatelet therapy is standard for patients undergoing percutaneous coronary intervention (PCI) with stents. Traditionally, patients swallow the loading dose of a P2Y12 inhibitor before or during PCI. Time to achieve adequate platelet inhibition after swallowing the loading dose varies significantly. Chewed tablets may allow more rapid inhibition of platelet aggregation. However, data for this strategy in patients with stable ischemic heart disease or non-ST-elevation acute coronary syndrome (NSTE-ACS) are less robust.

Methods

In this single-center prospective trial, 112 P2Y12-naïve patients with stable ischemic heart disease or NSTE-ACS on aspirin therapy and who received ticagrelor after coronary angiography but before PCI were randomized to chewing (n=55) o

SUBMITTER: Wilson TF 

PROVIDER: S-EPMC10117533 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature